Eradication of established tumors in mice by a combination antibody-based therapy

Nature Medicine

Volumn 12, Issue 6, 2006, Pages 693-698

  Uno, Tomoyasu ^a,b   Takeda, Kazuyoshi ^a,c   Kojima, Yuko ^a   Yoshizawa, Hirohisa ^d   Akiba, Hisaya ^a   Mittler, Robert S ^e   Gejyo, Fumitake ^b   Okumura, Ko ^a   Yagita, Hideo ^a   Smyth, Mark J ^c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD40 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY DR5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; FIBROSARCOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR CELL; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL RATE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744987907     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1405     Document Type: Article

References (30)

1. Johnstone, R.W., Ruefli, A.A. & Lowe, S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
2. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430 (2002).
3. Lake, R.A. & Robinson, B.W. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5, 397-405 (2005).
4. Pardoll, D. & Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. 10, 887-892 (2004).
5. Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
6. Croft, M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3, 609-620 (2003).
7. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22 (2004).
8. Smyth, M.J. et al. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 18, 1-6 (2003).
9. Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995).
10. Pitti, R.M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690 (1996).
11. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163 (1999).
12. Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891-4898 (2001).
13. Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954-960 (2001).
14. Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437-448 (2004).
15. French, R.R., Chan, H.T., Tutt, A.L. & Glennie, M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548-553 (1999).
16. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682-685 (1997).
17. + cytotoxic T cells. Leukemia 15, 1619-1626 (2001).
18. zum Buschenfelde, C.M., Hermann, C., Schmidt, B., Peschel, C. & Bernhard, H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62, 2244-2247 (2002).
19. Dhodapkar, K.M., Krasovsky, J., Williamson, B. & Dhodapkar, M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133 (2002).
20. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002).
21. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002).
22. Dunn, G.P., Old, L.J. & Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
23. Noguchi, Y., Jungbluth, A., Richards, E.C. & Old, L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA 93, 11798-11801 (1996).
24. Hayakawa, Y., Rovero, S., Forni, G. & Smyth, M.J. α-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA 100, 9464-9469 (2003).
25. Basombrio, M.A. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 30, 2458-2462 (1970).
26. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005 (2002).
27. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274 (2005).
28. Hurwitz, A.A., Yu, T.F., Leach, D.R. & Aliison, J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95, 10067-10071 (1998).
29. Hixon, J.A. et al. Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol. Blood Marrow Transplant. 8, 316-325 (2002).
30. Hamann, U., Eichmann, K. & Krammer, P.H. Frequencies and regulation of trinitrophenyl-specific cytotoxic T precursor cells: immunization results in release from suppression. J. Immunol. 130, 7-14 (1983).